Tag
This article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.
A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained b
Early Ib results from AstraZeneca’s AZD0120 (GC012F), a FasTCAR-derived BCMA/CD19 dual-target CAR‑T, reported 100% ORR in evaluable RRMM patients with low-grade CRS and no ICANS. Findings are encouraging but limited by small numbers and sho
In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and pla
A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicate
